Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page
- Check3 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record content with a generic error page; this change blocks access to the study's details and related sections.SummaryDifference16%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page shows Revision: v3.6.6, replacing v3.6.5, indicating a small maintenance update with no changes to the study details.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page now displays a new revision label, Revision: v3.6.5, replacing the previous Revision: v3.6.4, signaling a small update to the page's versioning. This change is a metadata update and does not affect the study content or eligibility details.SummaryDifference0.1%

- Check59 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4, indicating a new build of the page.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page’s revision label was updated from v3.6.2 to v3.6.3, indicating a small site update with no visible changes to the study details or eligibility criteria.SummaryDifference0.1%

- Check88 days agoChange DetectedThe revision tag on the page was updated from v3.6.0 to v3.6.2, signaling an internal update to the site's backend or documentation rather than any change to the clinical trial details presented.SummaryDifference0.1%

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.